Published in Biomed Res Int on November 19, 2013
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Five years of GWAS discovery. Am J Hum Genet (2012) 12.97
Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature (2008) 11.39
Autophagy in immunity and inflammation. Nature (2011) 11.16
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature (2008) 10.84
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood (2005) 5.82
Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
Crohn's disease. Lancet (2012) 4.42
Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells (2005) 4.26
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol (2010) 4.03
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet (2002) 4.03
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut (2011) 3.81
Genetics of type 1A diabetes. N Engl J Med (2009) 3.18
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol (2012) 3.15
Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut (2010) 3.09
Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum (2007) 3.08
Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) (2005) 3.00
Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut (2011) 2.91
Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell (2012) 2.87
Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant (2010) 2.50
A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res (2008) 2.38
Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol (2012) 2.36
Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol (2010) 2.27
Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med (2012) 2.19
Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum (2004) 2.18
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol (2009) 2.15
Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum (2005) 2.13
Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol (2009) 2.11
Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol (2005) 2.11
IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One (2010) 1.92
Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol (2012) 1.81
Multiple sclerosis. Annu Rev Med (2002) 1.80
Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther (2011) 1.76
Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med (2011) 1.72
Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther (2011) 1.70
Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant (2008) 1.68
Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens (2003) 1.66
Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther (2010) 1.63
Genetic variants in the autophagy pathway contribute to paediatric Crohn's disease. Gut (2008) 1.54
Adoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner. Cytotherapy (2012) 1.53
Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy (2013) 1.52
Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia (2009) 1.51
A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol (2005) 1.50
Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem (2009) 1.47
Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev (2012) 1.46
Journey of mesenchymal stem cells for homing: strategies to enhance efficacy and safety of stem cell therapy. Stem Cells Int (2012) 1.41
Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol (2007) 1.41
Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res (2012) 1.37
Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum (2004) 1.34
Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus (2009) 1.31
Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol (2010) 1.29
Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood (2012) 1.27
Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood (2008) 1.26
Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy (2011) 1.26
Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus (2007) 1.26
Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol (2009) 1.25
The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica (2008) 1.24
Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes (2010) 1.24
Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) (2006) 1.17
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev (2013) 1.16
Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Ann Rheum Dis (2012) 1.13
Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med (2013) 1.12
Autophagy as an important process in gut homeostasis and Crohn's disease pathogenesis. Gut (2008) 1.10
Activation of autophagy in mesenchymal stem cells provides tumor stromal support. Carcinogenesis (2011) 1.10
Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity (2012) 1.09
Mesenchymal stromal cells: a key player in 'innate tolerance'? Immunology (2012) 1.07
Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum (2009) 1.07
Concise review: mesenchymal stem cells for diabetes. Stem Cells Transl Med (2011) 1.06
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum (2010) 1.03
Genetics of Sjögren's syndrome in the genome-wide association era. J Autoimmun (2012) 1.01
Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol (2012) 1.01
Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming. Stem Cell Rev (2012) 1.01
Tag SNP screening of the PDCD1 gene for association with Graves' disease. Clin Endocrinol (Oxf) (2007) 0.98
The genetics of systemic sclerosis: an update. Clin Exp Rheumatol (2011) 0.98
Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol (2008) 0.97
PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. Hum Genet (2007) 0.96
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clin Exp Immunol (2013) 0.95
Human placenta-derived mesenchymal stem cells promote hepatic regeneration in CCl4 -injured rat liver model via increased autophagic mechanism. Stem Cells (2013) 0.95
Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus (2010) 0.94
Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler (2010) 0.92
New insights on translational development of mesenchymal stromal cells for suppressor therapy. J Cell Physiol (2012) 0.92
Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Exp Hematol (2010) 0.91
Links between autophagy, innate immunity, inflammation and Crohn's disease. Dig Dis (2009) 0.91
New insights into the genetics of immune responses in rheumatoid arthritis. Tissue Antigens (2012) 0.90
A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients. Lupus (2004) 0.89
Periodontal ligament stem cells regulate B lymphocyte function via programmed cell death protein 1. Stem Cells (2013) 0.89
Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmacogenet Genomics (2009) 0.88
Indoleamine 2,3 dioxygenase gene polymorphisms correlate with CD8+ Treg impairment in systemic sclerosis. Hum Immunol (2012) 0.86
Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. Eur J Endocrinol (2008) 0.86
Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. Autoimmunity (2008) 0.85
Ligands for programmed cell death 1 gene in patients with systemic lupus erythematosus. J Rheumatol (2007) 0.84